SCHEMBL917427

SCHEMBL917427

CCOC(=O)OC(C)OC(=O)[C@H]1CC[C@H](CN)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
PLG P00747 1/20 0.41
PLAT P00750 1/20 0.41
MAPT P10636 2/20 0.35
F2 P00734 1/20 0.35
SOAT1 P35610 1/20 0.35
SYK P43405 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ALDH1A1 P00352 2/20 0.33
GAA P10253 2/20 0.32
F11 P03951 1/20 0.32
KLKB1 P03952 1/20 0.32
CYP3A4 P08684 2/20 0.32
OPRK1 P41145 1/20 0.32
KDM4E B2RXH2 1/20 0.32
THRB P10828 1/20 0.32
HPGD P15428 1/20 0.32
TP53 P04637 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL917430 1.00 LMNA (0.41) LMNAPLGPLATMAPTF2
Hydrochloric Acid SCHEMBL5076170 0.99 LMNA (0.40) LMNAPLGPLATMAPTF2
Hydrochloric Acid SCHEMBL5076171 0.99 LMNA (0.40) LMNAPLGPLATMAPTF2
Hydrochloric Acid SCHEMBL10977530 0.86 PLG (0.50) LMNAPLGPLATF2KLKB1
Hydrochloric Acid SCHEMBL10973896 0.84 PLG (0.42) LMNAPLGPLATF2SYK
Hydrochloric Acid SCHEMBL10973889 0.84 PLG (0.42) LMNAPLGPLATF2SYK
SCHEMBL10973838 0.84 PLG (0.44) LMNAPLGPLATF2SYK
SCHEMBL10973845 0.84 PLG (0.44) LMNAPLGPLATF2SYK
SCHEMBL10978935 0.82 PLG (0.46) LMNAPLGPLATF2KLKB1
SCHEMBL5789042 0.80 PLG (0.53) LMNAPLGPLATMAPTF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0942746-B1 INHIBITION OF INVASIVE REMODELLING FONDEN TIL FREMME AF EKSPERIME (DK) 2005-03-16 EP claimed
US-8372881-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2013-02-12 US disclosed
US-20110184060-A1 ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A TRANEXAMIC ACID PRODRUG XENOPORT, INC. 2011-07-28 US disclosed
WO-2011091164-A1 ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A TRANEXAMIC ACID PRODRUG XENOPORT, INC. (US) 2011-07-28 WO disclosed
WO-2011028234-A1 USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID XENOPORT, INC. (US) 2011-03-10 WO disclosed
US-20110060040-A1 USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID XENOPORT, INC. 2011-03-10 US disclosed
US-20110009483-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE XENOPORT, INC. (US) 2011-01-13 US disclosed
US-7777070-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2010-08-17 US disclosed
EP-1919859-B1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID AND USE XENOPORT INC (US) 2010-06-02 EP disclosed
US-20100036148-A1 Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use XENOPORT, INC. (US) 2010-02-11 US disclosed
US-7592369-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2009-09-22 US disclosed
US-20080153898-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE XENOPORT, INC. 2008-06-26 US disclosed
EP-1919859-A2 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE Xenoport, Inc. (US) 2008-05-14 EP disclosed
US-7351740-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2008-04-01 US disclosed
US-20070027210-A1 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. 2007-02-01 US disclosed
WO-2007002013-A2 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE XENOPORT, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060040-A1 USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID PIGS, CPS1, ACMSD LMNA 1328/4885PLG 5/4885PLAT 9/4885
US-20070027210-A1 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use ACMSD, APEH, CPS1 LMNA 946/4885PLG 19/4885PLAT 17/4885
US-20110009483-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE ACMSD, APEH, CPS1 LMNA 946/4885PLG 19/4885PLAT 17/4885
US-20080153898-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE ACMSD, APEH, CPS1 LMNA 946/4885PLG 19/4885PLAT 17/4885
US-20110184060-A1 ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A TRANEXAMIC ACID PRODRUG F2, PROC, PLAT LMNA 1474/4885PLG 9/4885PLAT 3/4885
US-20100036148-A1 Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use ACMSD, APEH, CPS1 LMNA 946/4885PLG 19/4885PLAT 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.